Petros Grivas, MD, PhD, University of Washington, Seattle, WA, discusses KRAS G12C as an emerging target for urothelial carcinoma and the ongoing research into this rare, although important mutation. This interview was recorded at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.